Cerivastatin
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | < | + | <StructureSection load='' size='340' side='right' caption='Cerivastatin, also known as Baycol' scene='Cerivastatin/Ceriv/1'> |
===Better Known as: Baycol=== | ===Better Known as: Baycol=== | ||
* Marketed By: Bayer Healthcare<br /> | * Marketed By: Bayer Healthcare<br /> | ||
| Line 11: | Line 11: | ||
===Mechanism of Action=== | ===Mechanism of Action=== | ||
Cerivastatin is an inhibitor of [[HMG-CoA Reductase]] (HMGR), a highly <scene name='Cerivastatin/Chmg/1'>regulated enzyme</scene> responsible for the committed step in cholesterol synthesis.<ref>PMID:7784310</ref> Cerivastatin, like most of the statins, <scene name='Cerivastatin/Statin_ceriv/2'>binds HMGR</scene> via a number of polar interactions with the "cis loop" of HMGR, particularly residues Ser 684, Asp 690, Lys 691, Lys 692, and hydrogen bond interactions between Glu 559 and Asp 767 with the O5-hydroxyl of the statins. Van der Waals interactions between Leu 562, Val 683, Leu 853, Ala 856, and Leu 857 of HMGR and hydrophobic ring structures of Fluvastatin contribute to binding as well.<ref>PMID:11349148</ref> These interactions help Cerivastatin outcompete HMG-CoA, the substrate of HMGR, in binding to HMGR.<ref>PMID:7784310</ref> | Cerivastatin is an inhibitor of [[HMG-CoA Reductase]] (HMGR), a highly <scene name='Cerivastatin/Chmg/1'>regulated enzyme</scene> responsible for the committed step in cholesterol synthesis.<ref>PMID:7784310</ref> Cerivastatin, like most of the statins, <scene name='Cerivastatin/Statin_ceriv/2'>binds HMGR</scene> via a number of polar interactions with the "cis loop" of HMGR, particularly residues Ser 684, Asp 690, Lys 691, Lys 692, and hydrogen bond interactions between Glu 559 and Asp 767 with the O5-hydroxyl of the statins. Van der Waals interactions between Leu 562, Val 683, Leu 853, Ala 856, and Leu 857 of HMGR and hydrophobic ring structures of Fluvastatin contribute to binding as well.<ref>PMID:11349148</ref> These interactions help Cerivastatin outcompete HMG-CoA, the substrate of HMGR, in binding to HMGR.<ref>PMID:7784310</ref> | ||
| - | + | </StructureSection> | |
===Pharmacokinetics=== | ===Pharmacokinetics=== | ||
<table style="background: cellspacing="0px" align="" cellpadding="0px" width="42%"> | <table style="background: cellspacing="0px" align="" cellpadding="0px" width="42%"> | ||
Current revision
| |||||||||||
Pharmacokinetics
For References, See References |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
References
- ↑ Corsini A, Maggi FM, Catapano AL. Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol Res. 1995 Jan;31(1):9-27. PMID:7784310
- ↑ Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science. 2001 May 11;292(5519):1160-4. PMID:11349148 doi:10.1126/science.1059344
- ↑ Corsini A, Maggi FM, Catapano AL. Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol Res. 1995 Jan;31(1):9-27. PMID:7784310
